The Operations, Clinical Assessment and Administrative Core oversees this entire project and? is responsible for the conduct of the clinical trial and the collection of biological and behavioral? data. Based on studies of groups of major depressive disorder (MDD) patients, any single? psychotherapeutic or pharmacological strategy in clinical practice today achieves remission in only? a minority of patients. Thus the initial treatment an individual with MDD receives is largely an? accident of chance rather than an evidence based choice. Over a 5-year period, 400 treatment? naive patients with MDD will be recruited into a 12 week treatment trial of randomly assigned? treatment with an SSRI, escitalopram, a dual 5-HT/NE re-uptake inhibitor, duloxetine or cognitivebehavior? therapy (CBT). Subjects will be evaluated using state-of-the-art clinical assessments prior? to, during and at the end of acute treatment period. This core describes the efforts that will result in? the identification, recruitment of the patients, and assessment and delivery of the treatments. A? unique component of this proposal is the study of individuals with MDD not contaminated by? previous treatments that may confound measures of treatment response. Commensurate with the? CIDAR goals, the data generated in this core will provide the critical foundation for hypothesis? generation and testing in the other cores and projects.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZMH1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
United States
Zip Code
Syed, Shariful A; Beurel, Eléonore; Loewenstein, David A et al. (2018) Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response. Neuron 99:914-924.e3
Kelley, Mary E; Dunlop, Boadie W; Nemeroff, Charles B et al. (2018) Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse. Depress Anxiety 35:992-1000
Ahmed, Ahmed T; Frye, Mark A; Rush, A John et al. (2018) Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. J Affect Disord 238:1-7
Dunlop, Boadie W; Cole, Steven P; Nemeroff, Charles B et al. (2018) Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder. J Affect Disord 229:111-119
O'Connell, Chloe P; Goldstein-Piekarski, Andrea N; Nemeroff, Charles B et al. (2018) Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein. Am J Psychiatry 175:251-261
Berg, Joanna M; Kennedy, Jamie C; Dunlop, Boadie W et al. (2017) The Structure of Personality Disorders within a Depressed Sample: Implications for Personalizing Treatment. Pers Med Psychiatry 1-2:59-64
Ramirez-Mahaluf, Juan P; Roxin, Alexander; Mayberg, Helen S et al. (2017) A Computational Model of Major Depression: the Role of Glutamate Dysfunction on Cingulo-Frontal Network Dynamics. Cereb Cortex 27:660-679
Dunlop, Boadie W; Rajendra, Justin K; Craighead, W Edward et al. (2017) Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder. Am J Psychiatry 174:533-545
Dunlop, Boadie W; Kelley, Mary E; Aponte-Rivera, Vivianne et al. (2017) Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study. Am J Psychiatry 174:546-556
Drysdale, Andrew T; Grosenick, Logan; Downar, Jonathan et al. (2017) Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med 23:28-38

Showing the most recent 10 out of 41 publications